Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR, the “Company”), historically is an early-stage biotechnology company focused on the development of ribonucleic acid-directed nucleic acid therapeutics against validated targets. In September 2022, the Company announced a significant reduction in headcount, suspension of preclinical activities and discontinuation of all research and development, and that the Company was exploring strategic alternatives to maximize shareholder value.

Financial results second quarter 2024